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+ + +Binet A Binet B Binet C
664 175 28 5 0
78 5 1 0 0
77 2 1 0 0---
0 10 20 30 40
Time in years
Number of patients at risk
Supplementary Figure 1: Kaplan-Meier plot showing time to first treatment (TTFT) for
CLL patients stratified by Binet stage of disease. TTFT is defined as the time from diagnosis
of CLL to treatment or last follow-up without treatment. Patients censored at last follow-up are
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Supplementary Figure 2: Kaplan-Meier plot showing time to first treatment (TTFT) for
CLL patients stratified by IGHV status. TTFT is defined as the time from diagnosis of CLL
to treatment or last follow-up without treatment. Patients censored at last follow-up are indicated by
a cross. The number of patients in each group at each timepoint are indicated in the table.
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+ +CD38 negative CD38 positive
480 132 27 4 0
234 23 2 0 0--
0 10 20 30 40
Time in years
Number of patients at risk
Supplementary Figure 3: Kaplan-Meier plot showing time to first treatment (TTFT) for
CLL patients stratified by CD38 status. TTFT is defined as the time from diagnosis of CLL to
treatment or last follow-up without treatment. Patients censored at last follow-up are indicated by a
cross. The number of patients in each group at each timepoint are indicated in the table.
3
+























+ +≤ 3.5mg/L >3.5mg/L
198 109 42 9 2
91 34 10 3 1--
0 5 10 15 20
Time in years
Number of patients at risk
Supplementary Figure 4: Kaplan-Meier plot showing time to first treatment (TTFT) for
CLL patients stratified by β2 Microglobulin. TTFT is defined as the time from diagnosis
of CLL to treatment or last follow-up without treatment. Patients censored at last follow-up are
indicated by a cross. The number of patients in each group at each timepoint are indicated in the
table. High serum β2 microglobulin is defined as > 3.5 mg/L.
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Supplementary Figure 5: Kaplan-Meier plot showing time to first treatment (TTFT) for
CLL patients stratified by TP53 status. TTFT is defined as the time from diagnosis of CLL to
treatment or last follow-up without treatment. Patients censored at last follow-up are indicated by a
cross. The number of patients in each group at each timepoint are indicated in the table. Abnormal
is defined as a 17p deletion by FISH or a TP53 mutation by Sanger sequencing. It should be noted
that TP53 status is not routinely determined in patients with early stage CLL. As such, the cohort
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Supplementary Figure 6: Details of quality control filters applied to each CLL GWAS and data
analysis workflow. SNPs with a call rate < 95%, significant heterogeneity between studies (batch effect
P ≤ 10−3) or showing significant deviation from Hardy-Weinberg equilibrium (P ≤ 10−3) were excluded. Samples
were excluded due to low call rate (< 95%), ancestry (principle components analysis), relatedness (π ≥ 0.1875)
or heterozygosity (mean ±3× SD). Imputed SNPs with information score < 0.9 and MAF < 0.025 were excluded.
For each study, allelic dosage was estimated for the minor allele at each variant position and included in a
cox proportional hazard model to estimate hazard ratio (HR) and 95% confidence interval (CI). Study-specific
single nucleotide polymorphism (SNP) effects were combined using an inverse-variance-weighted method (fixed
effects model) and the DerSimonian-Laird approach (random effects model). SNPs with fixed-effect P values of
≤ 5 × 10−8 were deemed significant at genome-wide level.
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Supplementary Figure 7: Principal component analysis (PCA) plot of ethnicity structure
in CLL GWAS and 1000 genomes population panels. The first two principal components of
the analysis are plotted for CLL cases recruited to this study (crosses). 1000 genomes European
(EUR), East Asian (EAS) and African (AFR) individuals (open circles) are plotted in brown, pink
and gray, respectively. CLL cases of European ancestry included in subsequent analysis (top-left
corner) are shown in the inset together with 1000G EUR sub-populations (closed circles) comprising
CEU (Utah Residents (CEPH) with Northern and Western European Ancestry; pink), GBR (British
in England and Scotland; dark green), FIN (Finnish in Finland; orange), IBS (Iberian Population in




rs Identifier Primer sequences PCR conditions
rs736456
F 5’ CTGTTTGAGGCAGGCTTCTC 3’ 25 µL reactions included: 9 µL H2O, 12.5 µL Dream-
Taq Green PCR Master Mix (2X), 1.25 µL of each
forward and reverse primers (10 µM) and 50 ng DNA
(1 µL).
Cycling conditions: 2 minutes at 95 ◦C followed by
35 cycles (25 seconds at 95 ◦C, 35 seconds at 60 ◦C
and 45 seconds at 72 ◦C). Final step of 5 minutes at
72 ◦C with 4 ◦C hold.
R 5’ GAGCCCTTCCCTGAAAACCTC 3’
rs3778076
F 5’ CTACTTTCCCCGATGCCTGG 3’






Primer sequences PCR conditions
rs736456
F 5’ CTGTTTGAGGCAGGCTTCTC 3’
R 5’ GAGCCCTTCCCTGAAAACCTC 3’
25 μL reactions included: 9μL H2O, 12.5 μL DreamTaq 
Green PCR Master Mix (2X), 1.25 μL of each forward 
and reverse primers (10μM) and 5 DNA.
Cycling conditions: 2 minutes at 95˚C followed by 35 
cycles (25 seconds at 95˚C, 35 seconds at 60˚C and 45
seconds at 72˚C). Final step of 5 minutes at 72˚C with 
4˚C hold.
rs3778076
F 5’ CTACTTTCCCCGATGCCTGG 3’




rs Identifier Region Successful reads Concordance
rs736456 10q26.13 89/100 89/89 (100%)
rs3778076 6p 96/100 96/96 (100%)
2
Supplementary Figure 8: Sanger validation genotyping for rs736456 and rs3778076. Primer
sequences and PCR conditions for validation of rs736456 and rs3778076 (a). Representative genotype
results for rs736456 and rs3778076 (b). Concordance between GWAS genotyping and Sanger validation
genotyping for rs736456 and rs3778076 (c).
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Supplementary Figure 9: Quantile-Quantile plot of fixed-effect meta-analysis for time to
first treatment (TTFT). For each study, allelic dosage was estimated for the minor allele at each
variant position and included in a cox proportional hazard model to estimate hazard ratio (HR) and
95% confidence interval (CI). Variants were included in the meta-analysis if they had results from all
six studies. Study-specific single nucleotide polymorphism (SNP) effects were combined in a fixed
effect model using an inverse-variance-weighted method. Expected (under the null hypothesis of
no association) and observed distributions of -log10(P ) values are shown on the x-axis and y-axis,
respectively. The red line corresponds to y = x. Inflation lambda (λGC= 1.027) is the observed
median χ2 test statistic divided by the median expected χ2 test statistic under the null hypothesis.
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Supplementary Figure 10: Regional association and linkage disequilibrium plots for association
analysis conditioning on the top variant at each susceptibility locus for progressive CLL.
Regional association plots of time to first time treatment (TTFT) survival associations for the chromosome
10 (a) and chromosome 6 (b) loci conditioning on rs736456 and rs3778076, respectively. For each study,
Cox proportional hazard models were used to estimate the conditional results for each variant at the region
by including the top variant. The resulting effect sizes were combined using an inverse-variance-weighted
approach. All statistical tests were two-sided. SNP coordinates based on genomic build b37/hg19 are
shown on the x-axis and -log10 (P values) on the y-axis. Genotyped and imputed SNPs are represented by
diamonds and circles, respectively. SNPs are coloured according to their linkage disequilibrium (pairwise
r2) with the lead SNP (annotated) based on the 1000 Genomes European panel. Reference genes in the
region are shown in the lower panel, with arrows indicating transcript direction, dense blocks representing































 17.25%   1.06 [0.56, 2.01]
 13.03%   0.81 [0.39, 1.70]
  8.61%   0.58 [0.24, 1.44]
 29.74%   1.19 [0.73, 1.94]
  6.79%   0.69 [0.25, 1.91]
 24.57%   1.33 [0.78, 2.27]
100.00%   1.03 [0.79, 1.35]
1.03 [0.79, 1.35]Random−effect (P=8.01×10−1)
Study No/events Eff/Ref EAF Weight(%) HR [95% CI]
b
Fixed−effect (P=9.77×10−1)



























 19.03%   0.82 [0.37, 1.86]
 11.01%   0.99 [0.34, 2.89]
  8.40%   0.64 [0.19, 2.19]
 27.26%   1.72 [0.87, 3.40]
  7.31%   0.89 [0.24, 3.31]
 27.00%   0.77 [0.39, 1.53]
100.00%   0.99 [0.70, 1.42]
0.99 [0.70, 1.42]Random−effect (P=9.77×10−1)
Study No/events Eff/Ref EAF Weight(%) HR [95% CI]
Supplementary Figure 11: Forest plots showing associations between post-treatment sur-
vival and risk variants for progressive CLL. Forest plots for rs736456 (a) and rs3778076 (b)
and their age-adjusted association with post-treatment survival stratified by GWAS. Post-treatment
survival is defined as the time from first treatment for CLL-related symptoms to death or last
follow-up. No/events: Number of CLL patients/Number of patients receiving treatment; Eff/Ref:
effect/reference allele; EAF: effect allele frequency; HR: hazard ratio; CI: confidence interval; Squares
denote the per-allele HR, with size proportional to the weight of the study. Pooled HRs derived from
both the fixed and random-effects models are indicated by diamonds with their corresponding meta
P values shown in the left parentheses. X-axis label formats include reference sequence (rs) identifier
and chromosome:position (b37). P values for Cochran’s Q test (Phet) and I
2 for heterogeneity are
shown in parentheses. All statistical tests were two-sided.
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Binet A, rs736456 A/A
Binet A, rs736456 G/A or G/G
Binet B or C, rs736456 A/A
Binet B or C, rs736456 G/A or G/G
523 150 22 2 0
133 24 6 3 0
106 6 1 0 0





Number of patients at risk
b
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Binet A, rs3778076 C/C
Binet A, rs3778076 C/A or A/A
Binet B or C, rs3778076 C/C
Binet B or C, rs3778076 C/A or A/A
593 162 26 5 0
71 13 2 0 0
131 5 2 0 0





Number of patients at risk
Supplementary Figure 12: Kaplan-Meier plot showing time to first treatment (TTFT) for
CLL patients stratified by Binet stage of disease and SNP genotype for rs736456 (a)
and rs3778076 (b). P values are obtained from pairwise log-rank tests for survival curves, with
false discovery rate (FDR) corrections for multiple testing. For simplicity, p values are only shown for
the comparisions of SNP genotypes within the same prognostic factor stratum. TTFT is defined as
the time from diagnosis of CLL to treatment or last follow-up without treatment. Patients censored
at last follow-up are indicated by a cross. The number of patients in each group at each timepoint
are indicated in the table. All statistical tests were two-sided.
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Mutated, rs736456 G/A or G/G
Unmutated, rs736456 A/A
Unmutated, rs736456 G/A or G/G
306 114 18 2 0
72 17 5 3 0
125 7 1 0 0





Number of patients at risk
b
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Mutated, rs3778076 C/A or A/A
Unmutated, rs3778076 C/C
Unmutated, rs3778076 C/A or A/A
343 120 21 5 0
39 12 2 0 0
146 9 2 0 0





Number of patients at risk
Supplementary Figure 13: Kaplan-Meier plot showing time to first treatment (TTFT)
for CLL patients stratified by IGHV status and SNP genotype for rs736456 (a) and
rs3778076 (b). P values are obtained from pairwise log-rank tests for survival curves, with false
discovery rate (FDR) corrections for multiple testing. For simplicity, p values are only shown for the
comparisions of SNP genotypes within the same prognostic factor stratum. TTFT is defined as the
time from diagnosis of CLL to treatment or last follow-up without treatment. Patients censored at
last follow-up are indicated by a cross. The number of patients in each group at each timepoint are
indicated in the table. All statistical tests were two-sided.
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CD38 negative, rs736456 A/A
CD38 negative, rs736456 G/A or G/G
CD38 positive, rs736456 A/A
CD38 positive, rs736456 G/A or G/G
382 116 22 2 0
92 15 5 2 0
164 16 1 0 0





Number of patients at risk
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CD38 negative, rs3778076 C/C
CD38 negative, rs3778076 C/A or A/A
CD38 positive, rs3778076 C/C
CD38 positive, rs3778076 C/A or A/A
427 121 25 4 0
53 11 2 0 0
202 21 2 0 0





Number of patients at risk
Supplementary Figure 14: Kaplan-Meier plot showing time to first treatment (TTFT)
for CLL patients stratified by CD38 status and SNP genotype for rs736456 (a) and
rs3778076 (b). P values are obtained from pairwise log-rank tests for survival curves, with false
discovery rate (FDR) corrections for multiple testing. For simplicity, p values are only shown for the
comparisions of SNP genotypes within the same prognostic factor stratum. TTFT is defined as the
time from diagnosis of CLL to treatment or last follow-up without treatment. Patients censored at
last follow-up are indicated by a cross. The number of patients in each group at each timepoint are
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≤ 3.5mg/L, rs736456 A/A
≤ 3.5mg/L, rs736456 G/A or G/G
>3.5mg/L, rs736456 A/A
>3.5mg/L, rs736456 G/A or G/G
144 88 36 8 2
52 20 5 1 0
71 30 10 3 1
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≤ 3.5mg/L, rs3778076 C/C
≤ 3.5mg/L, rs3778076 C/A or A/A
>3.5mg/L, rs3778076 C/C
>3.5mg/L, rs3778076 C/A or A/A
174 102 39 8 2
24 7 3 1 0
73 29 9 3 1





Number of patients at risk
Supplementary Figure 15: Kaplan-Meier plot showing time to first treatment (TTFT) for
CLL patients stratified by β2 Microglobulin and SNP genotype for rs736456 (a) and
rs3778076 (b). P values are obtained from pairwise log-rank tests for survival curves, with false
discovery rate (FDR) corrections for multiple testing. For simplicity, p values are only shown for the
comparisions of SNP genotypes within the same prognostic factor stratum. TTFT is defined as the
time from diagnosis of CLL to treatment or last follow-up without treatment. Patients censored at
last follow-up are indicated by a cross. The number of patients in each group at each timepoint are






































Normal, rs736456 G/A or G/G
Abnormal, rs736456 A/A
Abnormal, rs736456 G/A or G/G
298 64 16 2 0
86 13 5 2 0
26 2 0 0 0





Number of patients at risk
b


































Normal, rs3778076 C/A or A/A
Abnormal, rs3778076 C/C
Abnormal, rs3778076 C/A or A/A
345 70 19 4 0
45 7 2 0 0
37 2 0 0 0





Number of patients at risk
Supplementary Figure 16: Kaplan-Meier plot showing time to first treatment (TTFT)
for CLL patients stratified by TP53 status and SNP genotype for rs736456 (a) and
rs3778076 (b). P values are obtained from pairwise log-rank tests for survival curves, with false
discovery rate (FDR) corrections for multiple testing. For simplicity, p values are only shown for
the comparisions of SNP genotypes within the same prognostic factor stratum. TTFT is defined as
the time from diagnosis of CLL to treatment or last follow-up without treatment. Patients censored
at last follow-up are indicated by a cross. The number of patients in each group at each timepoint
are indicated in the table. Abnormal is defined as a 17p deletion by FISH or a TP53 mutation by
Sanger sequencing. It should be noted that TP53 status is not routinely determined in patients with
early stage CLL. As such, the cohort tested for TP53 has an over-representation of patients with
progressive CLL. All statistical tests were two-sided.
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195 85 16 2 0
36 11 3 2 0
3 0 0 0 0−−
−










































214 90 17 4 0
22 7 2 0 0−−














































two or more risk variants
178 79 15 2 0
49 16 3 2 0
7 1 1 0 0−−
−













Number of patients at risk
Supplementary Figure 17: Survival curves in low-risk CLLs by rs736456 (a) rs3778076 (b)
and risk allele groups of rs736456 and rs3778076 (c). Low-risk CLL is defined as Binet stage
A patients with mutated IGHV and CD38 negativity (N=236). Numbers do not match 236 because
rs736456 genotypes are missing for 2 patients. Log-rank test is used to examine if survival curves






























































































































































































































23.7 23.8 23.9 24 24.1
Position on chr1 (Mb)
Supplementary Figure 18: Regional association plot of TTFT (time to first time treatment)
for known CLL etiological risk variant rs34676223. For each study, allelic dosage was estimated
for the minor allele at each variant position and included in a Cox proportional hazard model to
estimate hazard ratio (HR) and 95% confidence interval (CI). Variants were included in the meta-
analysis if they had results from all six studies. Study-specific single nucleotide polymorphism (SNP)
effects were combined in a fixed effect model using an inverse-variance-weighted method. The upper
panel shows SNP coordinates based on genomic build b37/hg19 on the x-axis, and -log10 (P values)
on the y-axis. Genotyped and imputed SNPs are represented by diamonds and circles, respectively,
and are coloured according to their linkage disequilibrium (pairwise r2) with the CLL etiological
risk variant based on the 1000 Genomes European panel. Reference genes in the region are shown
in the lower panel, with arrows indicating transcript direction, dense blocks representing exons and
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228.7 228.8 228.9 229 229.1
Position on chr1 (Mb)
Supplementary Figure 19: Regional association plot of TTFT (time to first time treatment)
for known CLL etiological risk variant rs41271473. For each study, allelic dosage was estimated
for the minor allele at each variant position and included in a Cox proportional hazard model to
estimate hazard ratio (HR) and 95% confidence interval (CI). Variants were included in the meta-
analysis if they had results from all six studies. Study-specific single nucleotide polymorphism (SNP)
effects were combined in a fixed effect model using an inverse-variance-weighted method. The upper
panel shows SNP coordinates based on genomic build b37/hg19 on the x-axis, and -log10 (P values)
on the y-axis. Genotyped and imputed SNPs are represented by diamonds and circles, respectively,
and are coloured according to their linkage disequilibrium (pairwise r2) with the CLL etiological
risk variant based on the 1000 Genomes European panel. Reference genes in the region are shown
in the lower panel, with arrows indicating transcript direction, dense blocks representing exons and











































































































































































































































































































































































































































































































































































































































37.4 37.5 37.6 37.7 37.8
Position on chr2 (Mb)
Supplementary Figure 20: Regional association plot of TTFT (time to first time treatment)
for known CLL etiological risk variant rs3770745. For each study, allelic dosage was estimated
for the minor allele at each variant position and included in a Cox proportional hazard model to
estimate hazard ratio (HR) and 95% confidence interval (CI). Variants were included in the meta-
analysis if they had results from all six studies. Study-specific single nucleotide polymorphism (SNP)
effects were combined in a fixed effect model using an inverse-variance-weighted method. The upper
panel shows SNP coordinates based on genomic build b37/hg19 on the x-axis, and -log10 (P values)
on the y-axis. Genotyped and imputed SNPs are represented by diamonds and circles, respectively,
and are coloured according to their linkage disequilibrium (pairwise r2) with the CLL etiological
risk variant based on the 1000 Genomes European panel. Reference genes in the region are shown
in the lower panel, with arrows indicating transcript direction, dense blocks representing exons and















































































































































































































































































































111.4 111.5 111.6 111.7 111.8
Position on chr2 (Mb)
Supplementary Figure 21: Regional association plot of TTFT (time to first time treatment)
for known CLL etiological risk variant rs13401811. For each study, allelic dosage was estimated
for the minor allele at each variant position and included in a Cox proportional hazard model to
estimate hazard ratio (HR) and 95% confidence interval (CI). Variants were included in the meta-
analysis if they had results from all six studies. Study-specific single nucleotide polymorphism (SNP)
effects were combined in a fixed effect model using an inverse-variance-weighted method. The upper
panel shows SNP coordinates based on genomic build b37/hg19 on the x-axis, and -log10 (P values)
on the y-axis. Genotyped and imputed SNPs are represented by diamonds and circles, respectively,
and are coloured according to their linkage disequilibrium (pairwise r2) with the CLL etiological
risk variant based on the 1000 Genomes European panel. Reference genes in the region are shown
in the lower panel, with arrows indicating transcript direction, dense blocks representing exons and
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111.6 111.7 111.8 111.9 112
Position on chr2 (Mb)
Supplementary Figure 22: Regional association plot of TTFT (time to first time treatment)
for known CLL etiological risk variant rs17483466. For each study, allelic dosage was estimated
for the minor allele at each variant position and included in a Cox proportional hazard model to
estimate hazard ratio (HR) and 95% confidence interval (CI). Variants were included in the meta-
analysis if they had results from all six studies. Study-specific single nucleotide polymorphism (SNP)
effects were combined in a fixed effect model using an inverse-variance-weighted method. The upper
panel shows SNP coordinates based on genomic build b37/hg19 on the x-axis, and -log10 (P values)
on the y-axis. Genotyped and imputed SNPs are represented by diamonds and circles, respectively,
and are coloured according to their linkage disequilibrium (pairwise r2) with the CLL etiological
risk variant based on the 1000 Genomes European panel. Reference genes in the region are shown
in the lower panel, with arrows indicating transcript direction, dense blocks representing exons and
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111.7 111.8 111.9 112 112.1
Position on chr2 (Mb)
Supplementary Figure 23: Regional association plot of TTFT (time to first time treatment)
for known CLL etiological risk variant rs9308731. For each study, allelic dosage was estimated
for the minor allele at each variant position and included in a Cox proportional hazard model to
estimate hazard ratio (HR) and 95% confidence interval (CI). Variants were included in the meta-
analysis if they had results from all six studies. Study-specific single nucleotide polymorphism (SNP)
effects were combined in a fixed effect model using an inverse-variance-weighted method. The upper
panel shows SNP coordinates based on genomic build b37/hg19 on the x-axis, and -log10 (P values)
on the y-axis. Genotyped and imputed SNPs are represented by diamonds and circles, respectively,
and are coloured according to their linkage disequilibrium (pairwise r2) with the CLL etiological
risk variant based on the 1000 Genomes European panel. Reference genes in the region are shown
in the lower panel, with arrows indicating transcript direction, dense blocks representing exons and
















































































































































































































































































































201.9 202 202.1 202.2 202.3
Position on chr2 (Mb)
Supplementary Figure 24: Regional association plot of TTFT (time to first time treatment)
for known CLL etiological risk variant rs3769825. For each study, allelic dosage was estimated
for the minor allele at each variant position and included in a Cox proportional hazard model to
estimate hazard ratio (HR) and 95% confidence interval (CI). Variants were included in the meta-
analysis if they had results from all six studies. Study-specific single nucleotide polymorphism (SNP)
effects were combined in a fixed effect model using an inverse-variance-weighted method. The upper
panel shows SNP coordinates based on genomic build b37/hg19 on the x-axis, and -log10 (P values)
on the y-axis. Genotyped and imputed SNPs are represented by diamonds and circles, respectively,
and are coloured according to their linkage disequilibrium (pairwise r2) with the CLL etiological
risk variant based on the 1000 Genomes European panel. Reference genes in the region are shown
in the lower panel, with arrows indicating transcript direction, dense blocks representing exons and
























































































































































































































































































































































































































































































































































































































230.9 231 231.1 231.2 231.3
Position on chr2 (Mb)
Supplementary Figure 25: Regional association plot of TTFT (time to first time treatment)
for known CLL etiological risk variant rs13397985. For each study, allelic dosage was estimated
for the minor allele at each variant position and included in a Cox proportional hazard model to
estimate hazard ratio (HR) and 95% confidence interval (CI). Variants were included in the meta-
analysis if they had results from all six studies. Study-specific single nucleotide polymorphism (SNP)
effects were combined in a fixed effect model using an inverse-variance-weighted method. The upper
panel shows SNP coordinates based on genomic build b37/hg19 on the x-axis, and -log10 (P values)
on the y-axis. Genotyped and imputed SNPs are represented by diamonds and circles, respectively,
and are coloured according to their linkage disequilibrium (pairwise r2) with the CLL etiological
risk variant based on the 1000 Genomes European panel. Reference genes in the region are shown
in the lower panel, with arrows indicating transcript direction, dense blocks representing exons and
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242.2 242.3 242.4 242.5 242.6
Position on chr2 (Mb)
Supplementary Figure 26: Regional association plot of TTFT (time to first time treatment)
for known CLL etiological risk variant rs757978. For each study, allelic dosage was estimated
for the minor allele at each variant position and included in a Cox proportional hazard model to
estimate hazard ratio (HR) and 95% confidence interval (CI). Variants were included in the meta-
analysis if they had results from all six studies. Study-specific single nucleotide polymorphism (SNP)
effects were combined in a fixed effect model using an inverse-variance-weighted method. The upper
panel shows SNP coordinates based on genomic build b37/hg19 on the x-axis, and -log10 (P values)
on the y-axis. Genotyped and imputed SNPs are represented by diamonds and circles, respectively,
and are coloured according to their linkage disequilibrium (pairwise r2) with the CLL etiological
risk variant based on the 1000 Genomes European panel. Reference genes in the region are shown
in the lower panel, with arrows indicating transcript direction, dense blocks representing exons and































































































































































































































































































































































































































































27.6 27.7 27.8 27.9 28
Position on chr3 (Mb)
Supplementary Figure 27: Regional association plot of TTFT (time to first time treatment)
for known CLL etiological risk variant rs9880772. For each study, allelic dosage was estimated
for the minor allele at each variant position and included in a Cox proportional hazard model to
estimate hazard ratio (HR) and 95% confidence interval (CI). Variants were included in the meta-
analysis if they had results from all six studies. Study-specific single nucleotide polymorphism (SNP)
effects were combined in a fixed effect model using an inverse-variance-weighted method. The upper
panel shows SNP coordinates based on genomic build b37/hg19 on the x-axis, and -log10 (P values)
on the y-axis. Genotyped and imputed SNPs are represented by diamonds and circles, respectively,
and are coloured according to their linkage disequilibrium (pairwise r2) with the CLL etiological
risk variant based on the 1000 Genomes European panel. Reference genes in the region are shown
in the lower panel, with arrows indicating transcript direction, dense blocks representing exons and
















































































































































































































































































































































































































































































39 39.1 39.2 39.3 39.4
Position on chr3 (Mb)
Supplementary Figure 28: Regional association plot of TTFT (time to first time treatment)
for known CLL etiological risk variant rs1274963. For each study, allelic dosage was estimated
for the minor allele at each variant position and included in a Cox proportional hazard model to
estimate hazard ratio (HR) and 95% confidence interval (CI). Variants were included in the meta-
analysis if they had results from all six studies. Study-specific single nucleotide polymorphism (SNP)
effects were combined in a fixed effect model using an inverse-variance-weighted method. The upper
panel shows SNP coordinates based on genomic build b37/hg19 on the x-axis, and -log10 (P values)
on the y-axis. Genotyped and imputed SNPs are represented by diamonds and circles, respectively,
and are coloured according to their linkage disequilibrium (pairwise r2) with the CLL etiological
risk variant based on the 1000 Genomes European panel. Reference genes in the region are shown
in the lower panel, with arrows indicating transcript direction, dense blocks representing exons and





























































































































































































































































































































































169.3 169.4 169.5 169.6 169.7
Position on chr3 (Mb)
Supplementary Figure 29: Regional association plot of TTFT (time to first time treatment)
for known CLL etiological risk variant rs10936599. For each study, allelic dosage was estimated
for the minor allele at each variant position and included in a Cox proportional hazard model to
estimate hazard ratio (HR) and 95% confidence interval (CI). Variants were included in the meta-
analysis if they had results from all six studies. Study-specific single nucleotide polymorphism (SNP)
effects were combined in a fixed effect model using an inverse-variance-weighted method. The upper
panel shows SNP coordinates based on genomic build b37/hg19 on the x-axis, and -log10 (P values)
on the y-axis. Genotyped and imputed SNPs are represented by diamonds and circles, respectively,
and are coloured according to their linkage disequilibrium (pairwise r2) with the CLL etiological
risk variant based on the 1000 Genomes European panel. Reference genes in the region are shown
in the lower panel, with arrows indicating transcript direction, dense blocks representing exons and
























































































































































































































































































































































































































































































102.5 102.6 102.7 102.8 102.9
Position on chr4 (Mb)
Supplementary Figure 30: Regional association plot of TTFT (time to first time treatment)
for known CLL etiological risk variant rs10028805. For each study, allelic dosage was estimated
for the minor allele at each variant position and included in a Cox proportional hazard model to
estimate hazard ratio (HR) and 95% confidence interval (CI). Variants were included in the meta-
analysis if they had results from all six studies. Study-specific single nucleotide polymorphism (SNP)
effects were combined in a fixed effect model using an inverse-variance-weighted method. The upper
panel shows SNP coordinates based on genomic build b37/hg19 on the x-axis, and -log10 (P values)
on the y-axis. Genotyped and imputed SNPs are represented by diamonds and circles, respectively,
and are coloured according to their linkage disequilibrium (pairwise r2) with the CLL etiological
risk variant based on the 1000 Genomes European panel. Reference genes in the region are shown
in the lower panel, with arrows indicating transcript direction, dense blocks representing exons and




















































































































































































































































































108.8 108.9 109 109.1 109.2
Position on chr4 (Mb)
Supplementary Figure 31: Regional association plot of TTFT (time to first time treatment)
for known CLL etiological risk variant rs898518. For each study, allelic dosage was estimated
for the minor allele at each variant position and included in a Cox proportional hazard model to
estimate hazard ratio (HR) and 95% confidence interval (CI). Variants were included in the meta-
analysis if they had results from all six studies. Study-specific single nucleotide polymorphism (SNP)
effects were combined in a fixed effect model using an inverse-variance-weighted method. The upper
panel shows SNP coordinates based on genomic build b37/hg19 on the x-axis, and -log10 (P values)
on the y-axis. Genotyped and imputed SNPs are represented by diamonds and circles, respectively,
and are coloured according to their linkage disequilibrium (pairwise r2) with the CLL etiological
risk variant based on the 1000 Genomes European panel. Reference genes in the region are shown
in the lower panel, with arrows indicating transcript direction, dense blocks representing exons and



















































































































































































































































































































































































































































































185.1 185.2 185.3 185.4 185.5
Position on chr4 (Mb)
Supplementary Figure 32: Regional association plot of TTFT (time to first time treatment)
for known CLL etiological risk variant rs57214277. For each study, allelic dosage was estimated
for the minor allele at each variant position and included in a Cox proportional hazard model to
estimate hazard ratio (HR) and 95% confidence interval (CI). Variants were included in the meta-
analysis if they had results from all six studies. Study-specific single nucleotide polymorphism (SNP)
effects were combined in a fixed effect model using an inverse-variance-weighted method. The upper
panel shows SNP coordinates based on genomic build b37/hg19 on the x-axis, and -log10 (P values)
on the y-axis. Genotyped and imputed SNPs are represented by diamonds and circles, respectively,
and are coloured according to their linkage disequilibrium (pairwise r2) with the CLL etiological
risk variant based on the 1000 Genomes European panel. Reference genes in the region are shown
in the lower panel, with arrows indicating transcript direction, dense blocks representing exons and























































































































































































































































































































































































































1.1 1.2 1.3 1.4 1.5
Position on chr5 (Mb)
Supplementary Figure 33: Regional association plot of TTFT (time to first time treatment)
for known CLL etiological risk variant rs31490. For each study, allelic dosage was estimated for
the minor allele at each variant position and included in a Cox proportional hazard model to estimate
hazard ratio (HR) and 95% confidence interval (CI). Variants were included in the meta-analysis if
they had results from all six studies. Study-specific single nucleotide polymorphism (SNP) effects
were combined in a fixed effect model using an inverse-variance-weighted method. The upper panel
shows SNP coordinates based on genomic build b37/hg19 on the x-axis, and -log10 (P values) on the
y-axis. Genotyped and imputed SNPs are represented by diamonds and circles, respectively, and are
coloured according to their linkage disequilibrium (pairwise r2) with the CLL etiological risk variant
based on the 1000 Genomes European panel. Reference genes in the region are shown in the lower
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HUS1B
0.2 0.3 0.4 0.5 0.6
Position on chr6 (Mb)
Supplementary Figure 34: Regional association plot of TTFT (time to first time treatment)
for known CLL etiological risk variant rs872071. For each study, allelic dosage was estimated
for the minor allele at each variant position and included in a Cox proportional hazard model to
estimate hazard ratio (HR) and 95% confidence interval (CI). Variants were included in the meta-
analysis if they had results from all six studies. Study-specific single nucleotide polymorphism (SNP)
effects were combined in a fixed effect model using an inverse-variance-weighted method. The upper
panel shows SNP coordinates based on genomic build b37/hg19 on the x-axis, and -log10 (P values)
on the y-axis. Genotyped and imputed SNPs are represented by diamonds and circles, respectively,
and are coloured according to their linkage disequilibrium (pairwise r2) with the CLL etiological
risk variant based on the 1000 Genomes European panel. Reference genes in the region are shown
in the lower panel, with arrows indicating transcript direction, dense blocks representing exons and




































































































































































































































































































































































































































































































2.8 2.9 3 3.1 3.2
Position on chr6 (Mb)
Supplementary Figure 35: Regional association plot of TTFT (time to first time treatment)
for known CLL etiological risk variant rs73718779. For each study, allelic dosage was estimated
for the minor allele at each variant position and included in a Cox proportional hazard model to
estimate hazard ratio (HR) and 95% confidence interval (CI). Variants were included in the meta-
analysis if they had results from all six studies. Study-specific single nucleotide polymorphism (SNP)
effects were combined in a fixed effect model using an inverse-variance-weighted method. The upper
panel shows SNP coordinates based on genomic build b37/hg19 on the x-axis, and -log10 (P values)
on the y-axis. Genotyped and imputed SNPs are represented by diamonds and circles, respectively,
and are coloured according to their linkage disequilibrium (pairwise r2) with the CLL etiological
risk variant based on the 1000 Genomes European panel. Reference genes in the region are shown
in the lower panel, with arrows indicating transcript direction, dense blocks representing exons and


















































































































































































































































































































































































































































































































































































































































































































































































































































































32.4 32.5 32.6 32.7 32.8
Position on chr6 (Mb)
Supplementary Figure 36: Regional association plot of TTFT (time to first time treatment)
for known CLL etiological risk variant rs674313. For each study, allelic dosage was estimated
for the minor allele at each variant position and included in a Cox proportional hazard model to
estimate hazard ratio (HR) and 95% confidence interval (CI). Variants were included in the meta-
analysis if they had results from all six studies. Study-specific single nucleotide polymorphism (SNP)
effects were combined in a fixed effect model using an inverse-variance-weighted method. The upper
panel shows SNP coordinates based on genomic build b37/hg19 on the x-axis, and -log10 (P values)
on the y-axis. Genotyped and imputed SNPs are represented by diamonds and circles, respectively,
and are coloured according to their linkage disequilibrium (pairwise r2) with the CLL etiological
risk variant based on the 1000 Genomes European panel. Reference genes in the region are shown
in the lower panel, with arrows indicating transcript direction, dense blocks representing exons and


















































































































































































































































































































































































































































































































































































































































































33.3 33.4 33.5 33.6 33.7
Position on chr6 (Mb)
Supplementary Figure 37: Regional association plot of TTFT (time to first time treatment)
for known CLL etiological risk variant rs210142. For each study, allelic dosage was estimated
for the minor allele at each variant position and included in a Cox proportional hazard model to
estimate hazard ratio (HR) and 95% confidence interval (CI). Variants were included in the meta-
analysis if they had results from all six studies. Study-specific single nucleotide polymorphism (SNP)
effects were combined in a fixed effect model using an inverse-variance-weighted method. The upper
panel shows SNP coordinates based on genomic build b37/hg19 on the x-axis, and -log10 (P values)
on the y-axis. Genotyped and imputed SNPs are represented by diamonds and circles, respectively,
and are coloured according to their linkage disequilibrium (pairwise r2) with the CLL etiological
risk variant based on the 1000 Genomes European panel. Reference genes in the region are shown
in the lower panel, with arrows indicating transcript direction, dense blocks representing exons and
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34.4 34.5 34.6 34.7 34.8
Position on chr6 (Mb)
Supplementary Figure 38: Regional association plot of TTFT (time to first time treatment)
for known CLL etiological risk variant rs3800461. For each study, allelic dosage was estimated
for the minor allele at each variant position and included in a Cox proportional hazard model to
estimate hazard ratio (HR) and 95% confidence interval (CI). Variants were included in the meta-
analysis if they had results from all six studies. Study-specific single nucleotide polymorphism (SNP)
effects were combined in a fixed effect model using an inverse-variance-weighted method. The upper
panel shows SNP coordinates based on genomic build b37/hg19 on the x-axis, and -log10 (P values)
on the y-axis. Genotyped and imputed SNPs are represented by diamonds and circles, respectively,
and are coloured according to their linkage disequilibrium (pairwise r2) with the CLL etiological
risk variant based on the 1000 Genomes European panel. Reference genes in the region are shown
in the lower panel, with arrows indicating transcript direction, dense blocks representing exons and






























































































































































































































































































































































































































































































154.3 154.4 154.5 154.6 154.7
Position on chr6 (Mb)
Supplementary Figure 39: Regional association plot of TTFT (time to first time treatment)
for known CLL etiological risk variant rs2236256. For each study, allelic dosage was estimated
for the minor allele at each variant position and included in a Cox proportional hazard model to
estimate hazard ratio (HR) and 95% confidence interval (CI). Variants were included in the meta-
analysis if they had results from all six studies. Study-specific single nucleotide polymorphism (SNP)
effects were combined in a fixed effect model using an inverse-variance-weighted method. The upper
panel shows SNP coordinates based on genomic build b37/hg19 on the x-axis, and -log10 (P values)
on the y-axis. Genotyped and imputed SNPs are represented by diamonds and circles, respectively,
and are coloured according to their linkage disequilibrium (pairwise r2) with the CLL etiological
risk variant based on the 1000 Genomes European panel. Reference genes in the region are shown
in the lower panel, with arrows indicating transcript direction, dense blocks representing exons and
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124.3 124.4 124.5 124.6 124.7
Position on chr7 (Mb)
Supplementary Figure 40: Regional association plot of TTFT (time to first time treatment)
for known CLL etiological risk variant rs17246404. For each study, allelic dosage was estimated
for the minor allele at each variant position and included in a Cox proportional hazard model to
estimate hazard ratio (HR) and 95% confidence interval (CI). Variants were included in the meta-
analysis if they had results from all six studies. Study-specific single nucleotide polymorphism (SNP)
effects were combined in a fixed effect model using an inverse-variance-weighted method. The upper
panel shows SNP coordinates based on genomic build b37/hg19 on the x-axis, and -log10 (P values)
on the y-axis. Genotyped and imputed SNPs are represented by diamonds and circles, respectively,
and are coloured according to their linkage disequilibrium (pairwise r2) with the CLL etiological
risk variant based on the 1000 Genomes European panel. Reference genes in the region are shown
in the lower panel, with arrows indicating transcript direction, dense blocks representing exons and





















































































































































































































































































































































































































































































































128 128.1 128.2 128.3 128.4
Position on chr8 (Mb)
Supplementary Figure 41: Regional association plot of TTFT (time to first time treatment)
for known CLL etiological risk variant rs2456449. For each study, allelic dosage was estimated
for the minor allele at each variant position and included in a Cox proportional hazard model to
estimate hazard ratio (HR) and 95% confidence interval (CI). Variants were included in the meta-
analysis if they had results from all six studies. Study-specific single nucleotide polymorphism (SNP)
effects were combined in a fixed effect model using an inverse-variance-weighted method. The upper
panel shows SNP coordinates based on genomic build b37/hg19 on the x-axis, and -log10 (P values)
on the y-axis. Genotyped and imputed SNPs are represented by diamonds and circles, respectively,
and are coloured according to their linkage disequilibrium (pairwise r2) with the CLL etiological
risk variant based on the 1000 Genomes European panel. Reference genes in the region are shown
in the lower panel, with arrows indicating transcript direction, dense blocks representing exons and
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Position on chr9 (Mb)
Supplementary Figure 42: Regional association plot of TTFT (time to first time treatment)
for known CLL etiological risk variant rs1679013. For each study, allelic dosage was estimated
for the minor allele at each variant position and included in a Cox proportional hazard model to
estimate hazard ratio (HR) and 95% confidence interval (CI). Variants were included in the meta-
analysis if they had results from all six studies. Study-specific single nucleotide polymorphism (SNP)
effects were combined in a fixed effect model using an inverse-variance-weighted method. The upper
panel shows SNP coordinates based on genomic build b37/hg19 on the x-axis, and -log10 (P values)
on the y-axis. Genotyped and imputed SNPs are represented by diamonds and circles, respectively,
and are coloured according to their linkage disequilibrium (pairwise r2) with the CLL etiological
risk variant based on the 1000 Genomes European panel. Reference genes in the region are shown
in the lower panel, with arrows indicating transcript direction, dense blocks representing exons and
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Supplementary Figure 43: Regional association plot of TTFT (time to first time treatment)
for known CLL etiological risk variant rs4406737. For each study, allelic dosage was estimated
for the minor allele at each variant position and included in a Cox proportional hazard model to
estimate hazard ratio (HR) and 95% confidence interval (CI). Variants were included in the meta-
analysis if they had results from all six studies. Study-specific single nucleotide polymorphism (SNP)
effects were combined in a fixed effect model using an inverse-variance-weighted method. The upper
panel shows SNP coordinates based on genomic build b37/hg19 on the x-axis, and -log10 (P values)
on the y-axis. Genotyped and imputed SNPs are represented by diamonds and circles, respectively,
and are coloured according to their linkage disequilibrium (pairwise r2) with the CLL etiological
risk variant based on the 1000 Genomes European panel. Reference genes in the region are shown
in the lower panel, with arrows indicating transcript direction, dense blocks representing exons and
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Position on chr11 (Mb)
Supplementary Figure 44: Regional association plot of TTFT (time to first time treatment)
for known CLL etiological risk variant rs61904987. For each study, allelic dosage was estimated
for the minor allele at each variant position and included in a Cox proportional hazard model to
estimate hazard ratio (HR) and 95% confidence interval (CI). Variants were included in the meta-
analysis if they had results from all six studies. Study-specific single nucleotide polymorphism (SNP)
effects were combined in a fixed effect model using an inverse-variance-weighted method. The upper
panel shows SNP coordinates based on genomic build b37/hg19 on the x-axis, and -log10 (P values)
on the y-axis. Genotyped and imputed SNPs are represented by diamonds and circles, respectively,
and are coloured according to their linkage disequilibrium (pairwise r2) with the CLL etiological
risk variant based on the 1000 Genomes European panel. Reference genes in the region are shown
in the lower panel, with arrows indicating transcript direction, dense blocks representing exons and
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Supplementary Figure 45: Regional association plot of TTFT (time to first time treatment)
for known CLL etiological risk variant rs735665. For each study, allelic dosage was estimated
for the minor allele at each variant position and included in a Cox proportional hazard model to
estimate hazard ratio (HR) and 95% confidence interval (CI). Variants were included in the meta-
analysis if they had results from all six studies. Study-specific single nucleotide polymorphism (SNP)
effects were combined in a fixed effect model using an inverse-variance-weighted method. The upper
panel shows SNP coordinates based on genomic build b37/hg19 on the x-axis, and -log10 (P values)
on the y-axis. Genotyped and imputed SNPs are represented by diamonds and circles, respectively,
and are coloured according to their linkage disequilibrium (pairwise r2) with the CLL etiological
risk variant based on the 1000 Genomes European panel. Reference genes in the region are shown
in the lower panel, with arrows indicating transcript direction, dense blocks representing exons and
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Position on chr12 (Mb)
Supplementary Figure 46: Regional association plot of TTFT (time to first time treatment)
for known CLL etiological risk variant rs10735079. For each study, allelic dosage was estimated
for the minor allele at each variant position and included in a Cox proportional hazard model to
estimate hazard ratio (HR) and 95% confidence interval (CI). Variants were included in the meta-
analysis if they had results from all six studies. Study-specific single nucleotide polymorphism (SNP)
effects were combined in a fixed effect model using an inverse-variance-weighted method. The upper
panel shows SNP coordinates based on genomic build b37/hg19 on the x-axis, and -log10 (P values)
on the y-axis. Genotyped and imputed SNPs are represented by diamonds and circles, respectively,
and are coloured according to their linkage disequilibrium (pairwise r2) with the CLL etiological
risk variant based on the 1000 Genomes European panel. Reference genes in the region are shown
in the lower panel, with arrows indicating transcript direction, dense blocks representing exons and




















































































































































































































































































































































































































































































40.2 40.3 40.4 40.5 40.6
Position on chr15 (Mb)
Supplementary Figure 47: Regional association plot of TTFT (time to first time treatment)
for known CLL etiological risk variant rs8024033. For each study, allelic dosage was estimated
for the minor allele at each variant position and included in a Cox proportional hazard model to
estimate hazard ratio (HR) and 95% confidence interval (CI). Variants were included in the meta-
analysis if they had results from all six studies. Study-specific single nucleotide polymorphism (SNP)
effects were combined in a fixed effect model using an inverse-variance-weighted method. The upper
panel shows SNP coordinates based on genomic build b37/hg19 on the x-axis, and -log10 (P values)
on the y-axis. Genotyped and imputed SNPs are represented by diamonds and circles, respectively,
and are coloured according to their linkage disequilibrium (pairwise r2) with the CLL etiological
risk variant based on the 1000 Genomes European panel. Reference genes in the region are shown
in the lower panel, with arrows indicating transcript direction, dense blocks representing exons and















































































































































































































































































































































































































































































































































































56.1 56.2 56.3 56.4 56.5
Position on chr15 (Mb)
Supplementary Figure 48: Regional association plot of TTFT (time to first time treatment)
for known CLL etiological risk variant rs7169431. For each study, allelic dosage was estimated
for the minor allele at each variant position and included in a Cox proportional hazard model to
estimate hazard ratio (HR) and 95% confidence interval (CI). Variants were included in the meta-
analysis if they had results from all six studies. Study-specific single nucleotide polymorphism (SNP)
effects were combined in a fixed effect model using an inverse-variance-weighted method. The upper
panel shows SNP coordinates based on genomic build b37/hg19 on the x-axis, and -log10 (P values)
on the y-axis. Genotyped and imputed SNPs are represented by diamonds and circles, respectively,
and are coloured according to their linkage disequilibrium (pairwise r2) with the CLL etiological
risk variant based on the 1000 Genomes European panel. Reference genes in the region are shown
in the lower panel, with arrows indicating transcript direction, dense blocks representing exons and





























































































































































































































































































































































































































































69.8 69.9 70 70.1 70.2
Position on chr15 (Mb)
Supplementary Figure 49: Regional association plot of TTFT (time to first time treatment)
for known CLL etiological risk variant rs7176508. For each study, allelic dosage was estimated
for the minor allele at each variant position and included in a Cox proportional hazard model to
estimate hazard ratio (HR) and 95% confidence interval (CI). Variants were included in the meta-
analysis if they had results from all six studies. Study-specific single nucleotide polymorphism (SNP)
effects were combined in a fixed effect model using an inverse-variance-weighted method. The upper
panel shows SNP coordinates based on genomic build b37/hg19 on the x-axis, and -log10 (P values)
on the y-axis. Genotyped and imputed SNPs are represented by diamonds and circles, respectively,
and are coloured according to their linkage disequilibrium (pairwise r2) with the CLL etiological
risk variant based on the 1000 Genomes European panel. Reference genes in the region are shown
in the lower panel, with arrows indicating transcript direction, dense blocks representing exons and
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83.1 83.2 83.3 83.4 83.5
Position on chr15 (Mb)
Supplementary Figure 50: Regional association plot of TTFT (time to first time treatment)
for known CLL etiological risk variant rs783540. For each study, allelic dosage was estimated
for the minor allele at each variant position and included in a Cox proportional hazard model to
estimate hazard ratio (HR) and 95% confidence interval (CI). Variants were included in the meta-
analysis if they had results from all six studies. Study-specific single nucleotide polymorphism (SNP)
effects were combined in a fixed effect model using an inverse-variance-weighted method. The upper
panel shows SNP coordinates based on genomic build b37/hg19 on the x-axis, and -log10 (P values)
on the y-axis. Genotyped and imputed SNPs are represented by diamonds and circles, respectively,
and are coloured according to their linkage disequilibrium (pairwise r2) with the CLL etiological
risk variant based on the 1000 Genomes European panel. Reference genes in the region are shown
in the lower panel, with arrows indicating transcript direction, dense blocks representing exons and






















































































































































































































































































































































































































































































































































































































85.7 85.8 85.9 86 86.1
Position on chr16 (Mb)
Supplementary Figure 51: Regional association plot of TTFT (time to first time treatment)
for known CLL etiological risk variant rs391525. For each study, allelic dosage was estimated
for the minor allele at each variant position and included in a Cox proportional hazard model to
estimate hazard ratio (HR) and 95% confidence interval (CI). Variants were included in the meta-
analysis if they had results from all six studies. Study-specific single nucleotide polymorphism (SNP)
effects were combined in a fixed effect model using an inverse-variance-weighted method. The upper
panel shows SNP coordinates based on genomic build b37/hg19 on the x-axis, and -log10 (P values)
on the y-axis. Genotyped and imputed SNPs are represented by diamonds and circles, respectively,
and are coloured according to their linkage disequilibrium (pairwise r2) with the CLL etiological
risk variant based on the 1000 Genomes European panel. Reference genes in the region are shown
in the lower panel, with arrows indicating transcript direction, dense blocks representing exons and


















































































































































































































































































































































































































































































































































































































































85.8 85.9 86 86.1 86.2
Position on chr16 (Mb)
Supplementary Figure 52: Regional association plot of TTFT (time to first time treatment)
for known CLL etiological risk variant rs305065. For each study, allelic dosage was estimated
for the minor allele at each variant position and included in a Cox proportional hazard model to
estimate hazard ratio (HR) and 95% confidence interval (CI). Variants were included in the meta-
analysis if they had results from all six studies. Study-specific single nucleotide polymorphism (SNP)
effects were combined in a fixed effect model using an inverse-variance-weighted method. The upper
panel shows SNP coordinates based on genomic build b37/hg19 on the x-axis, and -log10 (P values)
on the y-axis. Genotyped and imputed SNPs are represented by diamonds and circles, respectively,
and are coloured according to their linkage disequilibrium (pairwise r2) with the CLL etiological
risk variant based on the 1000 Genomes European panel. Reference genes in the region are shown
in the lower panel, with arrows indicating transcript direction, dense blocks representing exons and




















































































































































































































































































































































































































































































































































































































































85.8 85.9 86 86.1 86.2
Position on chr16 (Mb)
Supplementary Figure 53: Regional association plot of TTFT (time to first time treatment)
for known CLL etiological risk variant rs305061. For each study, allelic dosage was estimated
for the minor allele at each variant position and included in a Cox proportional hazard model to
estimate hazard ratio (HR) and 95% confidence interval (CI). Variants were included in the meta-
analysis if they had results from all six studies. Study-specific single nucleotide polymorphism (SNP)
effects were combined in a fixed effect model using an inverse-variance-weighted method. The upper
panel shows SNP coordinates based on genomic build b37/hg19 on the x-axis, and -log10 (P values)
on the y-axis. Genotyped and imputed SNPs are represented by diamonds and circles, respectively,
and are coloured according to their linkage disequilibrium (pairwise r2) with the CLL etiological
risk variant based on the 1000 Genomes European panel. Reference genes in the region are shown
in the lower panel, with arrows indicating transcript direction, dense blocks representing exons and















































































































































































































































































































































































































































































47.6 47.7 47.8 47.9 48
Position on chr18 (Mb)
Supplementary Figure 54: Regional association plot of TTFT (time to first time treatment)
for known CLL etiological risk variant rs1036935. For each study, allelic dosage was estimated
for the minor allele at each variant position and included in a Cox proportional hazard model to
estimate hazard ratio (HR) and 95% confidence interval (CI). Variants were included in the meta-
analysis if they had results from all six studies. Study-specific single nucleotide polymorphism (SNP)
effects were combined in a fixed effect model using an inverse-variance-weighted method. The upper
panel shows SNP coordinates based on genomic build b37/hg19 on the x-axis, and -log10 (P values)
on the y-axis. Genotyped and imputed SNPs are represented by diamonds and circles, respectively,
and are coloured according to their linkage disequilibrium (pairwise r2) with the CLL etiological
risk variant based on the 1000 Genomes European panel. Reference genes in the region are shown
in the lower panel, with arrows indicating transcript direction, dense blocks representing exons and


























































































































































































































































































































































































































































57.4 57.5 57.6 57.7 57.8
Position on chr18 (Mb)
Supplementary Figure 55: Regional association plot of TTFT (time to first time treatment)
for known CLL etiological risk variant rs4368253. For each study, allelic dosage was estimated
for the minor allele at each variant position and included in a Cox proportional hazard model to
estimate hazard ratio (HR) and 95% confidence interval (CI). Variants were included in the meta-
analysis if they had results from all six studies. Study-specific single nucleotide polymorphism (SNP)
effects were combined in a fixed effect model using an inverse-variance-weighted method. The upper
panel shows SNP coordinates based on genomic build b37/hg19 on the x-axis, and -log10 (P values)
on the y-axis. Genotyped and imputed SNPs are represented by diamonds and circles, respectively,
and are coloured according to their linkage disequilibrium (pairwise r2) with the CLL etiological
risk variant based on the 1000 Genomes European panel. Reference genes in the region are shown
in the lower panel, with arrows indicating transcript direction, dense blocks representing exons and




































































































































































































































































































































































































60.6 60.7 60.8 60.9 61
Position on chr18 (Mb)
Supplementary Figure 56: Regional association plot of TTFT (time to first time treatment)
for known CLL etiological risk variant rs4987855. For each study, allelic dosage was estimated
for the minor allele at each variant position and included in a Cox proportional hazard model to
estimate hazard ratio (HR) and 95% confidence interval (CI). Variants were included in the meta-
analysis if they had results from all six studies. Study-specific single nucleotide polymorphism (SNP)
effects were combined in a fixed effect model using an inverse-variance-weighted method. The upper
panel shows SNP coordinates based on genomic build b37/hg19 on the x-axis, and -log10 (P values)
on the y-axis. Genotyped and imputed SNPs are represented by diamonds and circles, respectively,
and are coloured according to their linkage disequilibrium (pairwise r2) with the CLL etiological
risk variant based on the 1000 Genomes European panel. Reference genes in the region are shown
in the lower panel, with arrows indicating transcript direction, dense blocks representing exons and
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Supplementary Figure 57: Regional association plot of TTFT (time to first time treatment)
for known CLL etiological risk variant rs7254272. For each study, allelic dosage was estimated
for the minor allele at each variant position and included in a Cox proportional hazard model to
estimate hazard ratio (HR) and 95% confidence interval (CI). Variants were included in the meta-
analysis if they had results from all six studies. Study-specific single nucleotide polymorphism (SNP)
effects were combined in a fixed effect model using an inverse-variance-weighted method. The upper
panel shows SNP coordinates based on genomic build b37/hg19 on the x-axis, and -log10 (P values)
on the y-axis. Genotyped and imputed SNPs are represented by diamonds and circles, respectively,
and are coloured according to their linkage disequilibrium (pairwise r2) with the CLL etiological
risk variant based on the 1000 Genomes European panel. Reference genes in the region are shown
in the lower panel, with arrows indicating transcript direction, dense blocks representing exons and
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Supplementary Figure 58: Regional association plot of TTFT (time to first time treatment)
for known CLL etiological risk variant rs11083846. For each study, allelic dosage was estimated
for the minor allele at each variant position and included in a Cox proportional hazard model to
estimate hazard ratio (HR) and 95% confidence interval (CI). Variants were included in the meta-
analysis if they had results from all six studies. Study-specific single nucleotide polymorphism (SNP)
effects were combined in a fixed effect model using an inverse-variance-weighted method. The upper
panel shows SNP coordinates based on genomic build b37/hg19 on the x-axis, and -log10 (P values)
on the y-axis. Genotyped and imputed SNPs are represented by diamonds and circles, respectively,
and are coloured according to their linkage disequilibrium (pairwise r2) with the CLL etiological
risk variant based on the 1000 Genomes European panel. Reference genes in the region are shown
in the lower panel, with arrows indicating transcript direction, dense blocks representing exons and
























































































































































































































































































































































































































































50.8 50.9 51 51.1 51.2
Position on chr22 (Mb)
Supplementary Figure 59: Regional association plot of TTFT (time to first time treatment)
for known CLL etiological risk variant rs140522. For each study, allelic dosage was estimated
for the minor allele at each variant position and included in a Cox proportional hazard model to
estimate hazard ratio (HR) and 95% confidence interval (CI). Variants were included in the meta-
analysis if they had results from all six studies. Study-specific single nucleotide polymorphism (SNP)
effects were combined in a fixed effect model using an inverse-variance-weighted method. The upper
panel shows SNP coordinates based on genomic build b37/hg19 on the x-axis, and -log10 (P values)
on the y-axis. Genotyped and imputed SNPs are represented by diamonds and circles, respectively,
and are coloured according to their linkage disequilibrium (pairwise r2) with the CLL etiological
risk variant based on the 1000 Genomes European panel. Reference genes in the region are shown
in the lower panel, with arrows indicating transcript direction, dense blocks representing exons and











































































































































































































































































































































































































































































































































































































































































123.8 123.9 124 124.1 124.2
Position on chr10 (Mb)
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Fixed−effect (P=3.79×10−8)



























 21.35%   1.61 [1.05, 2.46]
 12.75%   1.87 [1.08, 3.26]
 17.91%   1.89 [1.19, 3.01]
 25.59%   1.97 [1.33, 2.91]
  7.36%   1.88 [0.91, 3.90]
 15.05%   1.29 [0.78, 2.15]
100.00%   1.74 [1.43, 2.12]
1.74 [1.43, 2.12]Random−effect (P=3.79×10−8)
Study No/events Eff/Ref EAF Weight(%) HR [95% CI]
Supplementary Figure 60: Regional and forest plots of rs4752676. TTFT (time to first time
treatment) survival associations in rs4752676 region (a). The upper panel plots SNPs based on
genomic build b37/h19 coordinates on the x-axis, and their -log10(p-values) on the y-axis. Diamond
and circle shapes are used for genotyped and imputed SNPs, respectively, with colours according to
their pairwise r2 with the lead SNP based on 1000 Genomes European panel (Nov 2014). Reference
genes in the region are shown in the lower panel, with arrows indicating transcript direction, dense
blocks for exons, and lines for introns. Plot was generated using LocusZoom. Forest plot of rs4752676
effect on TTFT by study (b). No/events: No. CLL patients/No. patients receiving treatment (the
first time); Eff/Ref: effect/reference allele; EAF: frequencies of the effect allele; HR: hazard ratio; CI:
confidence interval; Squares denote the per-allele HR, with their size inversely proportional to the
variance of the effect estimates. Pooled HRs derived from both the fixed and random-effect models are
shown in diamond shapes, with their corresponding meta p-values indicated in the left parentheses.
Format of x-axis label is rsid, chromosome:position(b37), P for Cochran’s Q test (Phet) and I
2 for








































































































































































































































































































































































































































































































































































































































































123.8 123.9 124 124.1 124.2
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Fixed−effect (P=3.69×10−8)



























 21.31%   1.60 [1.05, 2.46]
 12.73%   1.88 [1.08, 3.26]
 18.01%   1.91 [1.20, 3.04]
 25.54%   1.96 [1.33, 2.90]
  7.35%   1.89 [0.91, 3.91]
 15.05%   1.29 [0.77, 2.14]
100.00%   1.74 [1.43, 2.12]
1.74 [1.43, 2.12]Random−effect (P=3.69×10−8)
Study No/events Eff/Ref EAF Weight(%) HR [95% CI]
Supplementary Figure 61: Regional and forest plots of rs736457. TTFT (time to first time
treatment) survival associations in rs736457 region (a). The upper panel plots SNPs based on genomic
build b37/h19 coordinates on the x-axis, and their -log10(p-values) on the y-axis. Diamond and
circle shapes are used for genotyped and imputed SNPs, respectively, with colours according to their
pairwise r2 with the lead SNP based on 1000 Genomes European panel (Nov 2014). Reference genes
in the region are shown in the lower panel, with arrows indicating transcript direction, dense blocks
for exons, and lines for introns. Plot was generated using LocusZoom. Forest plot of rs736457 effect
on TTFT by study (b). No/events: No. CLL patients/No. patients receiving treatment (the first
time); Eff/Ref: effect/reference allele; EAF: frequencies of the effect allele; HR: hazard ratio; CI:
confidence interval; Squares denote the per-allele HR, with their size inversely proportional to the
variance of the effect estimates. Pooled HRs derived from both the fixed and random-effect models are
shown in diamond shapes, with their corresponding meta p-values indicated in the left parentheses.
Format of x-axis label is rsid, chromosome:position(b37), P for Cochran’s Q test (Phet) and I
2 for
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Fixed−effect (P=4.12×10−8)



























 23.63%   1.58 [0.94, 2.65]
 12.48%   1.54 [0.75, 3.15]
 18.14%   2.27 [1.25, 4.11]
 20.40%   2.59 [1.48, 4.55]
  8.09%   2.75 [1.13, 6.70]
 17.26%   2.04 [1.11, 3.76]
100.00%   2.03 [1.58, 2.62]
2.03 [1.58, 2.62]Random−effect (P=4.12×10−8)
Study No/events Eff/Ref EAF Weight(%) HR [95% CI]
Supplementary Figure 62: Regional and forest plots of rs11757517. TTFT (time to first time
treatment) survival associations in rs11757517 region (a). The upper panel plots SNPs based on
genomic build b37/h19 coordinates on the x-axis, and their -log10(p-values) on the y-axis. Diamond
and circle shapes are used for genotyped and imputed SNPs, respectively, with colours according to
their pairwise r2 with the lead SNP based on 1000 Genomes European panel (Nov 2014). Reference
genes in the region are shown in the lower panel, with arrows indicating transcript direction, dense
blocks for exons, and lines for introns. Plot was generated using LocusZoom. Forest plot of rs11757517
effect on TTFT by study (b). No/events: No. CLL patients/No. patients receiving treatment (the
first time); Eff/Ref: effect/reference allele; EAF: frequencies of the effect allele; HR: hazard ratio; CI:
confidence interval; Squares denote the per-allele HR, with their size inversely proportional to the
variance of the effect estimates. Pooled HRs derived from both the fixed and random-effect models are
shown in diamond shapes, with their corresponding meta p-values indicated in the left parentheses.
Format of x-axis label is rsid, chromosome:position(b37), P for Cochran’s Q test (Phet) and I
2 for
heterogeneity in parenethesis. All statistical tests were two-sided.
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Supplementary Table 1: Demographic and clinical characteristics of chronic lymphocytic leukemia (CLL) cases
GWAS 1 GWAS 2 GWAS 3 GWAS 4 GWAS 5 GWAS 6 Study 7 P value*
Sex Male 84 86 90 82 31 101 49
Female 69 37 62 47 26 55 38 0.128
Not available 1 3 0 0 0 0 0
Age ≤ 65 70 49 87 64 32 56 36
>65 83 52 58 65 25 100 51 0.002
Not available 1 25 7 0 0 0 0
Binet stage A 134 107 126 107 48 87 70
B/C 18 18 24 21 9 57 9 4.39 × 10−8
Not available 2 1 2 1 0 12 8
IGHV Mutated 110 97 94 31 1 63 0
Unmutated 43 26 50 10 0 46 2 0.003
Not available 1 3 8 88 56 47 85
CD38 Negative 98 74 95 89 33 49 54
Positive 52 50 29 29 23 28 29 0.023
Not available 4 2 28 11 1 79 4
β2 Microglobulin ≤ 3.5 mgL−1 0 40 83 75 0 0 2
>3.5mgL−1 0 20 37 32 0 0 2 0.814
Not available 154 66 32 22 57 156 83
TP53 status Normal 135 14 30 5 1 139 70
Abnormal 3 3 6 2 0 17 9 0.002
Not available 16 109 116 122 56 0 8
GWAS, genome-wide association study; *Fishers exact test. All statistical tests were two-sided.
64
Supplementary Table 2: eQTL results for rs736456














rs736456 124012547 G 10 ENSG00000255624 RP11-564D11.3 124648738 0.07364703 0.3124953 1.7889
ENSG00000179988 PSTK 124735463 0.08726587 0.3124953 -1.71
ENSG00000107672 NSMCE4A 123725667 0.0961524 0.3124953 1.664
ENSG00000095574 IKZF5 124759327 0.13754382 0.320929072 -1.4849
ENSG00000154473 BUB3 124919339 0.14812111 0.320929072 1.4463
ENSG00000066468 FGFR2 123297910 0.23855749 0.443035339 -1.1785
ENSG00000107669 ATE1 123594127 0.41759542 0.562342092 0.8108
ENSG00000166033 HTRA1 124247732 0.41771032 0.562342092 -0.8103
ENSG00000119965 C10orf88 124702169 0.43257084 0.562342092 0.785
ENSG00000196177 ACADSB 124793161 0.72288928 0.854323695 -0.3546
ENSG00000138161 CUZD1 124615405 0.9349648 0.96378848 0.0818
ENSG00000213185 FAM24B 124623875 0.96378848 0.96378848 0.0455
ENSG00000107679 PLEKHA1 124163039 9.90E-17 1.28677E-15 8.3061
eQTL data for genes within 1MB of the risk SNP are shown. eQTL, expression quantitative trait loci; SNP, single nucleotide polymorphism.
aUnadjusted P value based on summary-data-based Mendelian randomization (SMR).
bBenjamini-Hochberg corrected P value.
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Supplementary Table 3: eQTL results for rs3778076














rs3778076 34513266 A 6 ENSG00000112039 FANCE 35427509 0.00083537 0.004646106 -3.3406
ENSG00000124507 PACSIN1 34468461 0.00086039 0.004646106 -3.3326
ENSG00000198755 RPL10A 35437373 0.01193704 0.05371668 -2.5139
ENSG00000023892 DEF6 35277571 0.0367798 0.141864943 2.0884
ENSG00000064999 ANKS1A 34958110 0.12283078 0.414553883 -1.5429
ENSG00000269490 SBP1 33663335 0.14700276 0.44100828 -1.4501
ENSG00000186577 C6orf1 34215702 0.22566553 0.609296931 -1.2115
ENSG00000137309 HMGA1 34209329 0.25121634 0.616621925 -1.1473
ENSG00000225339 RP11-513I15.6 34251000 0.30347967 0.667102562 1.029
ENSG00000220583 RPL35P2 34231269 0.32119753 0.667102562 0.9922
ENSG00000065029 ZNF76 35245224 0.35861887 0.691622106 -0.9179
ENSG00000137288 MNF1 33672424 0.42347908 0.762262344 -0.8002
ENSG00000146197 SCUBE3 35201523 0.47919369 0.779264312 0.7078
ENSG00000196114 RP3-391O22.3 34544234 0.4981522 0.779264312 0.6775
ENSG00000030110 BAK1 33544174 0.54664175 0.779264312 0.6029
ENSG00000161904 LEMD2 33747946 0.61918905 0.779264312 -0.497
ENSG00000112033 PPARD 35353151 0.65704258 0.779264312 -0.4439
ENSG00000112664 NUDT3 34308224 0.663998 0.779264312 -0.4344
ENSG00000124614 RPS10 34389566 0.67404719 0.779264312 -0.4205
ENSG00000266509 MIR3934 33665958 0.69535379 0.779264312 0.3916
ENSG00000096433 ITPR3 33626436 0.69683235 0.779264312 0.3896
ENSG00000007866 TEAD3 35453113 0.72154103 0.779264312 -0.3562
ENSG00000204188 GGNBP1 33554159 0.8424192 0.86674062 0.199
ENSG00000064995 TAF11 34850710 0.86674062 0.86674062 0.1679
ENSG00000065060 UHRF1BP1 34805386 2.49E-140 6.7281E-139 25.2188
ENSG00000196821 C6orf106 34609850 2.62E-65 3.53943E-64 17.0668
ENSG00000124562 SNRPC 34733377 7.57E-23 6.81399E-22 -9.8399
eQTL data for genes within 1MB of the risk SNP are shown. eQTL, expression quantitative trait loci; SNP, single nucleotide polymorphism.
aUnadjusted P value based on summary-data-based Mendelian randomization (SMR).
bBenjamini-Hochberg corrected P value.
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Supplementary Table 4: eQTL results for rs3800461














rs3800461 34616322 C 6 ENSG00000112039 FANCE 35427509 0.00100401 0.366527794 -3.2894
ENSG00000124507 PACSIN1 34468461 0.00367018 0.003137531 -2.9052
ENSG00000225339 RP11-513I15.6 34251000 0.00947011 0.010194944 2.5947
ENSG00000065029 ZNF76 35245224 0.01256734 0.023675275 2.4959
ENSG00000007866 TEAD3 35453113 0.0168943 0.028562136 2.389
ENSG00000112664 NUDT3 34308224 0.0313344 0.035196458 2.1529
ENSG00000186577 C6orf1 34215702 0.08235187 0.060258462 1.7372
ENSG00000269490 SBP1 33663335 0.13823389 0.147056911 -1.4822
ENSG00000064995 TAF11 34850710 0.21364682 0.230389817 -1.2436
ENSG00000196114 RP3-391O22.3 34544234 0.2492389 0.333823156 1.1523
ENSG00000137288 MNF1 33672424 0.27827613 0.386494625 -1.0842
ENSG00000161904 LEMD2 33747946 0.33344406 0.438742184 -0.9672
ENSG00000266509 MIR3934 33665958 0.4002359 0.481018595 0.8413
ENSG00000146197 SCUBE3 35201523 0.40405562 0.481018595 -0.8342
ENSG00000137309 HMGA1 34209329 0.55224461 0.627550693 -0.5943
ENSG00000096433 ITPR3 33626436 0.60376074 0.656261674 0.519
ENSG00000112033 PPARD 35353151 0.79162581 0.824610219 0.2644
ENSG00000220583 RPL35P2 34231269 0.98165027 0.98165027 -0.0229
ENSG00000124562 SNRPC 34733377 1.04E-60 8.66167E-60 -16.4368
ENSG00000064999 ANKS1A 34958110 1.24E-06 0.00000516 -4.8493
ENSG00000196821 C6orf106 34609850 3.27E-310 <1.00E-300 41.0453
ENSG00000065060 UHRF1BP1 34805386 3.27E-310 <1.00E-300 51.2666
ENSG00000023892 DEF6 35277571 4.10E-23 2.56556E-22 9.9014
ENSG00000124614 RPS10 34389566 5.19E-05 0.000185439 -4.0468
ENSG00000198755 RPL10A 35437373 5.31E-07 2.65445E-06 -5.0148
eQTL data for genes within 1MB of the risk SNP are shown. eQTL, expression quantitative trait loci; SNP, single nucleotide polymorphism.
aUnadjusted P value based on summary-data-based Mendelian randomization (SMR).
bBenjamini-Hochberg corrected P value.
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